【摘要】：目的本研究旨在評估厄貝沙坦在治療高血壓(HBP)合并糖尿病腎病(DN)患者中對腎病進(jìn)展的延緩作用。方法本研究為單中心、隨機、平行對照臨床試驗,共納入180例HBP合并DN患者�；颊甙凑諈^(qū)組隨機方式1∶1分配至厄貝沙坦組和氨氯地平組。結(jié)果治療12個月后,厄貝沙坦組估算腎小球濾過率(e GFR)下降值低于氨氯地平組(P=0.026)。CKDⅠ~Ⅱ期患者中,厄貝沙坦組e GFR下降值低于氨氯地平組(P=0.038),在CKDⅢ期患者中結(jié)果類似(P=0.042)。12個月時厄貝沙坦組24 h蛋白尿降低水平顯著高于氨氯地平組(P0.001),2組間DBP(P=0.534)和SBP(P=0.386)下降值無統(tǒng)計學(xué)差異。結(jié)論厄貝沙坦治療HBP合并DN患者,可以一定程度延緩患者的腎病進(jìn)展。
[Abstract]:Objective to evaluate the effect of irbesartan on the progression of hypertension (HBP) with diabetic nephropathy (DN). Methods 180 HBP patients with DN were enrolled in a single center, randomized, parallel controlled clinical trial. Patients were randomly assigned to irbesartan and amlodipine groups at 1:1. Results after 12 months of treatment, the decrease of estimated glomerular filtration rate (eGFR) in irbesartan group was lower than that in amlodipine group (P0. 026). The decrease of eGFR in irbesartan group was lower than that in amlodipine group (P0.038), and the results were similar in CKD 鈪，

本文編號：2123632